Moderna Rises, La-Z Boy Drops, Norfolk Southern Corp Climbs as Regulator Resumes Review of Bid From Rival

On this episode of Stock Movers:
- Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.
- La-Z Boy (LZB) shares tumble after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate. KeyBanc Capital Markets analyst Bradley Thomas says the company “issued F2Q sales and implied EPS guidance below consensus, pressured in part by continued investments”
- Norfolk Southern Corp (NSC) climbs after a federal regulator resumed its review of Union Pacific’s bid for the rival. The Surface Transportation Board established a procedural schedule for public comment, with participants having until Sept. 4 to file a notice of intent to participate in the review process.

See omnystudio.com/listener for privacy information.